Clareo Health | Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
* Intervention Model:
* Parallel: for all patients entering the trial
* Cross-over: for genotype 1b patients rolling over from NCT01428063 (AI447-028) who require rescue therapy after initial treatment in this study
* Peginterferon alfa-2a
* Ribavirin
* Daclatasvir
* Asunaprevir
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Prior participation in any BMS-790052, BMS-650032, or BMS-791325 trial and assigned to control arm (pegIFNα-2a/ribavirin + placebo) during the trial
Hepatitis C virus (HCV) genotype 1, 2, 3, or 4 (mixed genotypes are not permitted)
HCV RNA viral load detectable
You may not be if
Discontinuation from a prior BMS HCV clinical trial due to a pegIFNα-2a/ribavirin-related event
Any anti-HCV therapy following initial treatment with BMS-650032, BMS-790052, or BMS-791325
Positive for hepatitis B infection (hepatitis B surface antigen) or HIV-1 or HIV-2 antibody at screening
Evidence of medical condition associated with chronic liver disease other than HCV infection
Evidence of decompensated cirrhosis based on radiologic criteria or biopsy
